A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma'. Together they form a unique fingerprint.

Medicine & Life Sciences